Monitor for divesiran Phase 2 topline results in 3Q 2026, which will be a key catalyst for the stock. The updated presentation provides no new financial data or guidance, so near-term trading impact is limited.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 24 $9.16entry
- T+1 · 5mo ago +9.17%α +9.03% · $10.00
- T+5 · 5mo ago +14.63%α +12.92% · $10.50
- T+20 · 4mo ago +29.15%α +27.22% · $11.83
- T+60 · 2mo ago +38.65%α +35.81% · $12.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Silence Therapeutics filed an updated corporate presentation on June 23, 2026, highlighting pipeline progress across its siRNA programs. Key milestones include expected topline Phase 2 results for divesiran in polycythemia vera in 3Q 2026, Phase 1 data for SLN312 in dyslipidemia, and preclinical updates for SLN365 (GPR146) and SLN098 (INHBE). No financial data or guidance was provided.
Key Facts
- Filed updated corporate presentation under Item 7.01 Regulation FD Disclosure
- SANRECO Phase 2 study for divesiran (TMPRSS6) in polycythemia vera fully enrolled; topline results expected in 3Q 2026
- SLN312 (ANGPTL3) Phase 1 data presented at 2026 EAS Congress showing robust ANGPTL3 reductions; Silence to re-gain exclusive rights post-Phase 1
- SLN365 (GPR146) demonstrated >80% mRNA knockdown in NHP; potential IND filing in 2H 2027
- SLN098 (INHBE) showed ~90% protein knockdown sustained for at least 3 months in NHP; potential IND filing by year-end 2027
- Zerlasiran (LPA) described as Phase 3 ready; positioned for potential third-party partnership
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Clinical trial risks for divesiran Phase 2 and other pipeline programs
- Regulatory and competitive risks in siRNA therapeutics
- Dependence on partnership for zerlasiran advancement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-279577 |
| Document: sln-ex99_1.htm | 0001193125-26-279577 |
| Document: 0001193125-26-279577-index-headers.html | 0001193125-26-279577 |
| Document: 0001193125-26-279577-index.html | 0001193125-26-279577 |
| Document: 0001193125-26-279577.txt | 0001193125-26-279577 |
Track record
15 reports on SLN
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers